Asgard Therapeutics to present preclinical data on lead asset AT-108, a personalized, off-the-shelf gene therapy, at AACR Annual Meeting 2026
This image was generated by AI and may not depict real events.
Asgard Therapeutics will present preclinical data on its lead gene therapy asset AT-108 at the AACR Annual Meeting 2026, demonstrating its potential in cancer treatment. AT-108 uses in vivo cell reprogramming to induce a personalized anti-tumor immune response.
Asgard Therapeutics, a biotech company based in Lund, Sweden, is set to present preclinical data on its lead gene therapy asset AT-108 at the AACR Annual Meeting 2026 in San Diego, California. AT-108 utilizes in vivo cell reprogramming technology to directly reprogram tumor cells into dendritic cells, inducing a personalized anti-tumor immune response. The presentation will detail preclinical data showing AT-108's systemic, dose-dependent efficacy with broad tumor activity. Asgard is progressing AT-108 toward clinical development, focusing on solid tumors, and is advancing IND-enabling studies and CMC development. The company's technology aims to set in motion efficient and personalized immune responses against cancer.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.